Cardiac Safety Services Market by Type (Standalone, Integrated), Services (ECG/Holter Measurement, Blood Pressure Measurement, Cardiac Imaging, Thorough QT Studies), End User (Pharmaceutical & Biopharma, CROs), Region - Global Forecast to 2028

"Launch of cardiac safety services is driving the growth of the cardiac safety services market"

The global cardiac safety services market is projected to reach USD 1,282 million by 2028 from USD 739 million in 2023, at a CAGR of 11.6% during the forecast period of 2023 to 2028. The growth of this market can be attributed to the rising incidence of cardiovascular diseases, increasing research and development activities, and increasing outsourcing of cardiac safety services. For instance, The active pharmaceutical drug pipeline is increasing annually, primarily led by an increase in research activities. Pharmaceutical companies are increasingly outsourcing research activities to academic organizations and Contract Research Organizations (CROs) to stay competitive and retain focus on core functions. The R&D tasks primarily outsourced range from basic research to late-stage development, genetic engineering, target validation, assay development, hit exploration & lead optimization (hit candidates-as-a-service), safety studies/tests in animal models, and clinical trials involving humans. The growing pipeline of pharmaceutical companies is a key reason attributing to the high outsourcing of services.

"The pharmaceutical and biopharmaceutical companies segment accounted for the largest share by end user during the forecast period"

Download Free Sample PDF @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=2713715

In 2022, pharmaceutical & biopharmaceutical companies segment accounted for the largest share by end user in the global cardiac safety services market. Cardiac safety services are utilized by pharmaceutical and biopharmaceutical companies to oversee clinical trials for newly developed drugs, with these companies dedicated to the development of innovative treatments for diverse medical conditions and diseases. These companies are required to provide precise data pertaining to drug development and subsequently complete applications for submission to regulatory authorities. Cardiac safety concerns frequently lead to the discontinuation of potentially promising drugs during their development, creating a substantial demand for cardiac safety services within the pharmaceutical and biopharmaceutical companies.

"Europe: The second largest region in the cardiac safety services market"

Europe accounted for the second-largest market for cardiac safety services market after North America. The European cardiac safety services market has witnessed significant growth in recent years, driven by demographic changes, such as the growing incidence of chronic diseases. This is attributed to the rising geriatric population in the region. As per the European Commission, by 2025, more than 20% of Europeans are expected to be 65 years and above, with a rapid increase in the number of people aged 80 years and above, indicating strong demand growth for healthcare services. This will drive pharmaceutical and biopharmaceutical clinical trial activity for novel drug discoveries and directly contribute to the growth of associated markets, such as cardiac safety services.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side- 70% and Demand Side 30%
By Designation: C-level - 50%, D-level - 20%, and Others - 30%
By Region: North America -35%, Europe -24%, Asia-Pacific -25%, Latin America - 10%, Middle East - 4% & Africa- 2%

List of Companies Profiled in the Report:

Laboratory Corporation of America Holdings (US)
Medpace (US)
Koninklijke Philips N.V. (Netherland)
Clario (US)
Ncardia (Netherlands)
IQVIA (US)
Certara (US)
PPD Inc. (Part of Thermo Fisher Scientific, Inc.) (US)
SGS S.A. (Switzerland)
ICON Plc (Ireland)
WuXi AppTec (China)
Charles River Laboratories (US)
Eurofins Scientific (Luxembourg)
Frontage Labs (US)
Banook Group (France)
Biotrial (France)
Celerion (US)
Richmond Pharmacology (UK)
PhysioStim (France)
Shanghai Medicilon Inc. (China)
ACM Global Laboratories (India)
Worldwide Clinical Trials (US)
Nova Research Laboratories LLC (US)
Biobeat (Israel)
CRS. Experts. Early Phase. (Germany)

Research Coverage:

This report provides a detailed picture of the cardiac safety services market. It aims at estimating the size and future growth potential of the market across different segments such as the type, service type, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Download Complete Report @ https://www.reportsnreports.com/purchase.aspx?name=2713715

ReportsnReports - Your Market Research Librarian
Corporate Headquarters
Tower B5, office 101, Magarpatta SEZ,
Hadapsar, Pune-411013, India.
+ 1 347 333 3771
sales@reportsandreports.com

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

This release was published on openPR.